REG - Hikma Pharmaceutical - Acquisition

Hikma PharmaceuticalsAnnouncement

17/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220117:nRSQ6414Ya&default-theme=true

RNS Number : 6414Y  Hikma Pharmaceuticals Plc  17 January 2022

Hikma expands into Canada with acquisition of Teligent sterile injectable
assets

London, 17 January 2022 - Hikma Pharmaceuticals PLC (Hikma), the multinational
pharmaceutical company, today announces that it has agreed to acquire the
Canadian assets of Teligent Inc. (Teligent) for $45.75 million. The
transaction is expected to be completed before the end of the first quarter of
2022.

The acquisition marks Hikma's expansion into Canada and includes a portfolio
of 25 sterile injectable products, three in-licenced ophthalmic products and a
pipeline of seven additional products, four of which are approved by Health
Canada.

Riad Mishlawi, President of Hikma Injectables, commented, "This acquisition
further expands our portfolio of essential sterile injectable medicines and
gives Hikma an entry into the highly attractive Canadian injectables market.
The combination of our sales and marketing expertise and this portfolio of
exciting products will enable us to expand our North American business and
develop a solid position in this important market."

In October 2021, Teligent filed for voluntary protection under Chapter 11 of
the U.S. Bankruptcy Code.  As part of this process, Teligent initiated a sale
of its core assets, following which Hikma has agreed to acquire Teligent's
Canadian assets.

 

- ENDS -

Enquiries:

Hikma (Investors):

 Susan Ringdal                                                              +44 (0)20 7399 2760/ +44 (0)7776 477050

 EVP, Strategic Planning and Global Affairs
 Guy Featherstone                                                           +44 (0)20 3892 4389/ +44 (0)7795 896738

 Senior Investor Relations
 Manager
 Layan Kalisse                                                              +44 (0)20 7399 2788/ +44 (0)7970 709912

 Investor Relations Analyst

 

Teneo (Press):
 

 Charles Armitstead          +44 (0)7703 330 269

 US Media

 Steven Weiss/David Belian

                             +1 732 788 8279/ +1 848 254 4875

 

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and
BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people
around the world. For more than 40 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
the United States (US), the Middle East and North Africa (MENA) and Europe,
and we use our unique insight and expertise to transform cutting-edge science
into innovative solutions that transform people's lives. We're committed to
our customers, and the people they care for, and by thinking creatively and
acting practically, we provide them with a broad range of branded and
non-branded generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a leading
licensing partner, and through our venture capital arm, are helping bring
innovative health technologies to people around the world. For more
information, please visit: www.hikma.com
(https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2531421-1%26h%3D3823969217%26u%3Dhttp%253A%252F%252Fwww.hikma.com%252F%26a%3Dwww.hikma.com&data=02%7C01%7Csweiss%40Hikma.com%7C4a35048c8c764c63c86308d70efbac9e%7C178c1a723d3c40afbaa754615303bcdc%7C0%7C1%7C636994346427346162&sdata=lHZaoOb0u30Y6re6yfLW1Ar4vvBS%2FnjEUNdB00TBaTI%3D&reserved=0)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQUBSNRUVUAARR